Company intelligence / Profile preview
Genevant Sciences
Vancouver, British Columbia, Canada
- Ownership
- Private
- Employees
- ~54
- Development stage
- Other
01
Overview
Genevant’s LNP and ligand conjugate platforms have supported partner programs from discovery to clinical trials, including the first and only FDA-approved systemic RNA-LNP drug (patisiran) and promising clinical-stage gene editing and RNA therapies; multiple programs in collaboration and licensing/partner arrangements are in preclinical, IND-enabling, and clinical stages
- Therapeutic areas
- Infectious DiseasesRare DiseasesGastroenterologyHematologyCardiovascularOncology
- Modalities
- Lipid nanoparticle delivery therapymRNA-based drugsSmall interfering RNARNA therapyGene therapyLigand conjugate delivery therapy
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →03
Partnerships
Beyond the preview
Go deeper on Genevant Sciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Genevant Sciences.